Jonathan Yen-Wen Yu Sells 300 Shares of Disc Medicine (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) COO Jonathan Yen-Wen Yu sold 300 shares of the company’s stock in a transaction on Friday, June 26th. The shares were sold at an average price of $72.50, for a total value of $21,750.00. Following the completion of the transaction, the chief operating officer owned 54,324 shares of the company’s stock, valued at $3,938,490. The trade was a 0.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Jonathan Yen-Wen Yu also recently made the following trade(s):

• On Monday, June 22nd, Jonathan Yen-Wen Yu sold 9,700 shares of Disc Medicine stock. The stock was sold at an average price of $72.66, for a total value of $704,802.00.
• On Tuesday, June 16th, Jonathan Yen-Wen Yu sold 18,612 shares of Disc Medicine stock. The shares were sold at an average price of $69.19, for a total value of $1,287,764.28.

Disc Medicine Trading Down 1.8%

Shares of NASDAQ IRON traded down $1.36 on Tuesday, reaching $73.14. 729,507 shares of the company traded hands, compared to its average volume of 612,517. Disc Medicine, Inc. has a fifty-two week low of $40.00 and a fifty-two week high of $99.50. The company has a 50 day moving average of $68.99 and a 200 day moving average of $70.77. The company has a current ratio of 24.00, a quick ratio of 24.00 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $2.79 billion, a PE ratio of -11.05 and a beta of 0.93.

Disc Medicine (NASDAQ:IRON) last released its earnings results on Tuesday, May 5th. The company reported ($1.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.62) by ($0.03). On average, equities research analysts forecast that Disc Medicine, Inc. will post -6.74 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on IRON shares. Wedbush reiterated an “outperform” rating and issued a $88.00 price target on shares of Disc Medicine in a report on Wednesday, June 10th. Morgan Stanley upped their price objective on Disc Medicine from $80.00 to $85.00 and gave the stock an “overweight” rating in a report on Monday, June 15th. Wall Street Zen raised Disc Medicine from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Wells Fargo & Company lifted their target price on Disc Medicine from $78.00 to $79.00 and gave the company an “overweight” rating in a report on Monday, March 2nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Disc Medicine in a research report on Monday, April 20th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Disc Medicine has an average rating of “Moderate Buy” and a consensus price target of $105.80.

Institutional Investors Weigh In On Disc Medicine

Several large investors have recently made changes to their positions in IRON. ANTIPODES PARTNERS Ltd purchased a new position in shares of Disc Medicine in the 4th quarter valued at $33,000. Aster Capital Management DIFC Ltd purchased a new stake in Disc Medicine during the 3rd quarter worth $38,000. KBC Group NV acquired a new stake in Disc Medicine in the 4th quarter valued at $80,000. Persistent Asset Partners Ltd acquired a new stake in Disc Medicine in the 4th quarter valued at $141,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in Disc Medicine by 36.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,834 shares of the company’s stock valued at $146,000 after purchasing an additional 490 shares during the period. Institutional investors and hedge funds own 83.70% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.